Eribulin Mesylate and Lorlatinib

• Generic Name: eribulin
• Dosage Forms: n.a.
• Other Brand Names: Halaven

Treatment of metastatic breast cancer in patients who have previously received at least 2 chemotherapeutic regimens, including an anthracycline and a taxane, in either the adjuvant or metastatic setting.

There is no generally accepted standard of care for management of advanced and heavily pretreated anthracycline- and taxane-refractory metastatic breast cancer. Some clinicians recommend individualizing therapy based on factors such as patient’s disease stage and tumor type, performance status, quality of life, preferences, treatment history (e.g., toxicity), underlying medical conditions, and expected benefits and risks of each option.

• Generic Name: lorlatinib
• Dosage Forms: n.a.
• Other Brand Names: Lorbrena

Lorlatinib is used to treat a certain type of non-small cell lung cancer that has spread to other parts of the body.

Lorlatinib is used only if your cancer has a specific genetic marker (an abnormal "ALK" gene). Your doctor will test you for this gene.

Lorlatinib is given after other cancer treatments did not work or have stopped working.

Lorlatinib was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to lorlatinib, but further studies are needed.

Lorlatinib may also be used for purposes not listed in this medication guide.